170 related articles for article (PubMed ID: 38330178)
1. Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT.
Gurnari C; Koster L; Baaij L; Heiblig M; Yakoub-Agha I; Collin M; Passweg J; Bulabois CE; Khan A; Loschi M; Carnevale-Schianca F; Crisà E; Caravelli D; Kuball J; Saraceni F; Olivieri A; Rambaldi A; Kulasekararaj AG; Hayden PJ; Badoglio M; Onida F; Scheid C; Franceschini F; Mekinian A; Savic S; Voso MT; Drozd-Sokolowska J; Snowden JA; Raj K; Alexander T; Robin M; Greco R; McLornan DP
Blood Adv; 2024 Mar; 8(6):1444-1448. PubMed ID: 38330178
[No Abstract] [Full Text] [Related]
2. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT.
Gurnari C; Robin M; Godley LA; Drozd-Sokołowska J; Włodarski MW; Raj K; Onida F; Worel N; Ciceri F; Carbacioglu S; Kenyon M; Aljurf M; Bonfim C; Makishima H; Niemeyer C; Fenaux P; Zebisch A; Hamad N; Chalandon Y; Hellström-Lindberg E; Voso MT; Mecucci C; Duarte FB; Sebert M; Sicre de Fontbrune F; Soulier J; Shimamura A; Lindsley RC; Maciejewski JP; Calado RT; Yakoub-Agha I; McLornan DP
Lancet Haematol; 2023 Dec; 10(12):e994-e1005. PubMed ID: 37898151
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic Hematopoietic Cell Transplantation Is Safe and Effective Treatment in Patients with Myelodysplastic Syndromes Seventy Years and Older.
Mukherjee S
Biol Blood Marrow Transplant; 2017 Jan; 23(1):1-2. PubMed ID: 27865911
[No Abstract] [Full Text] [Related]
4. [Two cases of VEXAS syndrome].
Gunnarsson K; Vivar Pomiano N; Tesi B; Tobiasson M; Creignou M; Ungerstedt J
Lakartidningen; 2022 Sep; 119():. PubMed ID: 36082915
[TBL] [Abstract][Full Text] [Related]
5. Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?
Robin M; Fenaux P
Leukemia; 2020 Oct; 34(10):2552-2560. PubMed ID: 32661295
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report.
Loschi M; Roux C; Sudaka I; Ferrero-Vacher C; Marceau-Renaut A; Duployez N; Passeron T; Cluzeau T
Bone Marrow Transplant; 2022 Feb; 57(2):315-318. PubMed ID: 34999727
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.
Heidenreich S; Ziagkos D; de Wreede LC; van Biezen A; Finke J; Platzbecker U; Niederwieser D; Einsele H; Bethge W; Schleuning M; Beelen DW; Tischer J; Nagler A; Glass B; Maertens J; Yáñez L; Beguin Y; Sill H; Scheid C; Stelljes M; Ganser A; Zachée P; Selleslag D; de Witte T; Robin M; Kröger N
Biol Blood Marrow Transplant; 2017 Jan; 23(1):44-52. PubMed ID: 27720995
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.
Shah NN; Bacher U; Fry T; Calvo KR; Stetler-Stevenson M; Arthur DC; Kurlander R; Baird K; Wise B; Giralt S; Bishop M; Hardy NM; Wayne AS
Am J Hematol; 2012 Sep; 87(9):916-22. PubMed ID: 22473867
[No Abstract] [Full Text] [Related]
9. Toward a pathophysiology inspired treatment of VEXAS syndrome.
Heiblig M; Patel BA; Groarke EM; Bourbon E; Sujobert P
Semin Hematol; 2021 Oct; 58(4):239-246. PubMed ID: 34802546
[TBL] [Abstract][Full Text] [Related]
10. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
11. Impact of T-cell depletion on outcome of patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome.
Raboud M; Beauverd Y; Simonetta F; Dantin C; Pradier A; Tsopra O; Koutsi A; Mamez AC; Stephan C; Rodriguez Morales JF; Polchlopek-Blasiak K; Tirefort Y; Masouridi-Levrat S; Chalandon Y
Bone Marrow Transplant; 2018 Aug; 53(8):1072-1075. PubMed ID: 29515245
[No Abstract] [Full Text] [Related]
12. Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.
Cremers EM; van Biezen A; de Wreede LC; Scholten M; Vitek A; Finke J; Platzbecker U; Beelen D; Schwerdtfeger R; Volin L; Harhalakis N; Blijlevens N; Nagler A; Kröger N; de Witte T
Ann Hematol; 2016 Dec; 95(12):1971-1978. PubMed ID: 27650829
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation.
Odenike O; Onida F; Padron E
Am Soc Clin Oncol Educ Book; 2015; ():e398-412. PubMed ID: 25993202
[TBL] [Abstract][Full Text] [Related]
14. Second allogeneic stem cell transplantation in a patient with hypoplastic myelodysplastic syndrome following a primary diagnosis of aplastic anaemia.
Ocheni S; Oyekunle A; Kröger N; Ayuk F; Klyuchnikov E; Arps S; Held K; Zabelina T; Adjallé R; Wolschke C; Zander AR; Bacher U
Acta Haematol; 2011; 125(3):175-8. PubMed ID: 21196720
[No Abstract] [Full Text] [Related]
15. The Art of Transplantation: Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation.
Ragon BK
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e71-e72. PubMed ID: 30562588
[TBL] [Abstract][Full Text] [Related]
16. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients.
Mangaonkar AA; Langer KJ; Lasho TL; Finke C; Litzow MR; Hogan WJ; Shah MV; Go RS; Bartoo G; Kutzke J; McCullough KB; Koster M; Samec M; Warrington KJ; Reichard KK; Olteanu H; Riwes M; Patnaik MM; Alkhateeb HB
Am J Hematol; 2023 Feb; 98(2):E28-E31. PubMed ID: 36403135
[No Abstract] [Full Text] [Related]
17. Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience.
Al-Hakim A; Poulter JA; Mahmoud D; Rose AMS; Elcombe S; Lachmann H; Cargo C; Duncan CJA; Bishton M; Bigley V; Khan A; Savic S
Br J Haematol; 2022 Dec; 199(5):777-781. PubMed ID: 36184391
[No Abstract] [Full Text] [Related]
18. Principles and overview of allogeneic hematopoietic stem cell transplantation.
Giralt S; Bishop MR
Cancer Treat Res; 2009; 144():1-21. PubMed ID: 19779888
[No Abstract] [Full Text] [Related]
19. Successful treatment of myelodysplastic syndrome and Behcet colitis after allogeneic hematopoietic stem cell transplantation.
Kook MH; Yhim HY; Lee NR; Song EK; Kim HS; Yim CY; Kwak JY
Korean J Intern Med; 2014 Jan; 29(1):123-5. PubMed ID: 24574844
[No Abstract] [Full Text] [Related]
20. [Place of hematopoietic stem cell transplantation in the treatment of myelodysplastic syndromes].
Kroschinsky F; Bornhäuser M; Ehninger G
Med Klin (Munich); 2001 Mar; 96(3):135-43. PubMed ID: 11315397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
